Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingxuan Zhike Granule is a Traditional Chinese Medicine (TCM) hospital preparation developed by the **Yunnan Provincial Hospital of Traditional Chinese Medicine**. It is formulated based on classical TCM principles to treat respiratory conditions characterized by "wind-heat" syndrome. The preparation is primarily indicated for the treatment of influenza, acute bronchitis, and upper respiratory tract infections, specifically targeting symptoms such as cough, fever, sore throat, and yellow sputum. Its pharmacological action is attributed to a combination of herbal ingredients—typically including Mulberry Leaf (*Morus alba*), Chrysanthemum, and Apricot Kernel—which collectively exert antitussive, anti-inflammatory, and mild antiviral effects. During public health emergencies, including the COVID-19 pandemic and seasonal influenza outbreaks, it has been included in regional treatment protocols in Yunnan Province as a recommended therapy for symptomatic relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingxuan zhike granule.